Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis

Biologic disease-modifying antirheumatic drugs (DMARDs) such as adalimumab, etanercept and infliximab are effective at reducing symptoms and slowing progression of rheumatoid arthritis (RA). These drugs act more quickly, require less laboratory monitoring, and are better tolerated than nonbiologic DMARDs, but they are also up to 100 times more expensive.

1 Jun 2009

Researchers identify mechanism by which an anti-TNF therapy impairs host defense against tuberculosis

The life of many individuals with inflammatory diseases such as rheumatoid arthritis has been dramatically improved by treatment with drugs that target the protein TNF, so called anti-TNF therapies.

20 Apr 2009

Infliximab after intestinal resective surgery may help prevent post-op Crohn's disease recurrence

The administration of infliximab after intestinal resective surgery was found to be effective at preventing endoscopic and histological recurrence of Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

2 Feb 2009

Musculoskeletal Center wins $2.2 million to study biologics safety

The UAB Center for Education and Research on Therapeutics has won a $2.2 million federal grant to study the risks and benefits of a class of drugs called ‘biologics' -- genetically engineered agents targeting the immune system of patients with rheumatoid arthritis, Crohn's disease, psoriasis and other autoimmune disorders.

18 Nov 2008

First-ever international guidelines for the treatment of psoriatic arthritis

Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.

26 Oct 2008

Outlook for Crohn's disease improves due to new therapies

A study led by Mayo Clinic has found that infliximab (Remicade) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone.

6 Oct 2008

Discovery of new genes for inflammatory bowel disease in children

Researchers have discovered two new genes that increase the risk of developing inflammatory bowel disease (IBD) in childhood.

31 Aug 2008

Access to rheumatoid arthritis drugs 'curbed' for sufferers in the UK

Sufferers of rheumatoid arthritis in Britain have been warned that their access to a particularly effective class of drug will in future be limited.

20 Jul 2008

Could arthritis wonder drugs provide clues for all disease?

Drugs that have helped treat millions of rheumatoid arthritis sufferers may hold the key to many more medical conditions, including atherosclerosis - a leading cause of heart disease - says the researcher who jointly invented and developed them.

From The University of Manchester 17 Jul 2008

Biological medicine helps more people with rheumatoid arthritis

Patients who have recently developed rheumatoid arthritis respond better to treatment with biological medicine in combination with conventional pharmacological medicine. This according to results of the Swefot national clinical study, which is to be presented at an international rheumatology congress in Paris by scientists from Swedish Karolinska Institutet and Karolinska University Hospital, who conducted the study in association with another 15 rheumatology units in Sweden.

15 Jun 2008

Researchers who helped millions with arthritis receive Janssen Award

Two British researchers who pioneered treatments which have helped millions of people with rheumatoid arthritis and other autoimmune diseases have been awarded the prestigious 2008 Dr. Paul Janssen Award for Biomedical Research, announced today.

13 May 2008

Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients

For elderly and disabled rheumatoid arthritis (RA) sufferers, the Medicare Prescription Drug Improvement and Modernization Act (MMA) brought the promise of better disease management with "biologic" drugs.

15 Apr 2008

Effect of tumor necrosis factor a inhibitors on heart failure risk in rheumatoid arthritis

A chronic autoimmune disease, rheumatoid arthritis (RA) is characterized by persistent inflammation of the synovial membrane and progressive joint destruction.

28 Feb 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

Combining medications often best strategy to battle rheumatoid arthritis

For patients with rheumatoid arthritis, combining one well-known, lower cost synthetic drug with one of six biologic medications often works best to reduce joint swelling or tenderness, according to a new report funded by the Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services.

18 Dec 2007

Combining medications often best strategy to battle rheumatoid arthritis

For patients with rheumatoid arthritis, combining one well-known, lower-cost synthetic drug with one of six biologic medications often works best to reduce joint swelling or tenderness, according to a new report by researchers at the RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center, which is sponsored by the Agency for Healthcare Research and Quality.

19 Nov 2007

New insight into ulcerative colitis

Social, environmental and dietary changes are associated with the changes of disease spectrum in a country. Ulcerative colitis has become a commonly seen disease in China, probably due to extensive consumption of Western foods in recent years.

14 Nov 2007

Infliximab scheduled treatment has proven to be an effective strategy in IBD patients

Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients.

25 Oct 2007

Biologic treatment for rheumatoid arthritis and the risk of cancer

The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated.

30 Aug 2007